<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugResultsOutput hits="20" offset="0" totalResults="3231"><SearchResults><Drug id="99924" name="sodium phenylbutyrate + tauroursodeoxycholic acid (oral, ALS/Alzheimers disease), Amylyx" lastModificationDate="2019-04-12T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Amylyx Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Amylyx Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Alzheimers disease</Indication><Indication>Motor neurone disease</Indication></IndicationsPrimary><ActionsPrimary><Action>Histone deacetylase inhibitor</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Amylyx is developing AMX-0035, a fixed dose combination of sodium phenylbutyrate, a histone deacetylase inhibitor, and tauroursodeoxycholic acid, for the potential oral treatment of amyotrophic lateral sclerosis (ALS) and for the potential prevention or slowing of progression of Alzheimer's disease [ 1714297 ], [ 1781443 ], [ 1973830 ], [ 2038292 ]. In June 2017, a phase II trial for ALS was initiated [ 1922290 ]. In August 2018, a phase II trial in patients with late mild cognitive impairment or</Summary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Antioxidant agent</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="9990" name="cisplatin + epinephrine, Matrix" lastModificationDate="2016-11-26T00:00:00Z" phaseHighest="Discontinued"><CompanyOriginator>Matrix Pharmaceutical Inc</CompanyOriginator><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><Technologies><Technology>Drug combination</Technology><Technology>Drug implant</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>IntraDose is an injectable, collagen gel-based drug delivery system which was under development by Matrix, and had been submitted for regulatory approval, for the potential delivery of anticancer drugs to solid tumors [ 303924 ], [ 304018 ]. In March 2002, Chiron acquired Matrix was seeking to outlicense IntraDose , although the submission was not withdrawn [ 445191 ], [ 445315 ], [ 455561 ]; however, by March 2003, Chiron had stopped development [ 481460 ].</Summary><CompaniesSecondary><Company>Chiron Corp</Company><Company>Matrix Pharmaceutical Inc</Company></CompaniesSecondary><IndicationsSecondary><Indication>Breast tumor</Indication><Indication>Esophagus tumor</Indication><Indication>Head and neck tumor</Indication><Indication>Liver tumor</Indication><Indication>Lung tumor</Indication><Indication>Melanoma</Indication><Indication>Neoplasm</Indication><Indication>Prostate tumor</Indication><Indication>Rectal tumor</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="99862" name="tadekinig alfa, AB2 Bio" lastModificationDate="2019-01-08T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>AB2 Bio Ltd</CompanyOriginator><CompaniesPrimary><Company>AB2 Bio Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Adult onset Stills disease</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Macrophage activation syndrome</Indication><Indication>Xerophthalmia</Indication></IndicationsPrimary><ActionsPrimary><Action>Interleukin 18 ligand inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>AB2 Bio is developing tadekinig alfa (recombinant human interleukin-18 binding protein; IL-18 BP), which targets IL-18, for the potential sc treatment of systemic inflammatory diseases including adult onset Still's disease and macrophage-activation syndrome. The company is also investigating the drug for the potential treatment of dry eye disease and Chronic Obstructive Pulmonary Disease (COPD) [ 1716427 ], [ 1798089 ], [ 1918793 ]. In February 2017, a phase III trial was initiated in infantile macrophage-activation</Summary><IndicationsSecondary><Indication>Hemophagocytic lymphohistiocytosis</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action></ActionsSecondary><AddedDate>2015-11-17T00:00:00Z</AddedDate></Drug><Drug id="99850" name="arsenic trioxide (oral, acute promyelocytic leukemia), Orsenix Holdings" lastModificationDate="2019-06-27T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>Orsenix Holdings BV</CompanyOriginator><CompaniesPrimary><Company>Orsenix Holdings BV</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Acute myelogenous leukemia</Indication><Indication>Hematological neoplasm</Indication></IndicationsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Orsenix Holdings is developing ORH-2014, an oral capsule formulation of arsenic trioxide, for the potential treatment of hematological cancers, including acute promyelocytic leukemia (APL) and acute myeloid leukemia (AML) [ 1712786 ], [ 1904967 ], [ 1738218 ]. In December 2016, a phase I study was initiated in patients with advanced hematological cancers [ 1904967 ]; in June 2018, data were presented [ 2045635 ], [ 2045477 ]; in December 2018, the trial was ongoing [ 1904967 ].</Summary><IndicationsSecondary><Indication>Acute promyelocytic leukemia</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action></ActionsSecondary><AddedDate>2015-11-17T00:00:00Z</AddedDate></Drug><Drug id="99831" name="fosmanogepix" lastModificationDate="2019-06-24T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Amplyx Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Amplyx Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Aspergillus infection</Indication><Indication>Blastomyces infection</Indication><Indication>Candida infection</Indication><Indication>Coccidioides infection</Indication><Indication>Cryptococcus infection</Indication><Indication>Fungal infection</Indication><Indication>Fusarium infection</Indication><Indication>Mucorales infection</Indication><Indication>Scedosporium infection</Indication></IndicationsPrimary><ActionsPrimary><Action>GPI anchored wall transfer protein 1 inhibitor</Action></ActionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Amplyx Pharmaceuticals , under license from Eisai , is developing fosmanogepix (APX-001; E-1211), a prodrug of the active moiety APX-001A (E-1210), a Gwt1 fungal enzyme inhibitor, for the potential iv and oral treatment of fungal infection, including candidiasis, invasive aspergillosis, rare molds and coccidioidomycosis [ 1126565 ], [ 1130589 ], [ 1248143 ], [ 1712278 ], [ 1772582 ]. In October 2018, a phase II trial was initiated in non-neutropenic patients with candidemia, with or without</Summary><CompaniesSecondary><Company>Eisai Co Ltd</Company></CompaniesSecondary><ActionsSecondary><Action>Fungicide</Action></ActionsSecondary><AddedDate>2015-11-17T00:00:00Z</AddedDate></Drug><Drug id="99812" name="bendamustine (oral, chronic lymphocytic leukemia), Exinda Therapeutics" lastModificationDate="2016-12-07T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Exinda Therapeutics LLC</CompanyOriginator><CompaniesPrimary><Company>Exinda Therapeutics LLC</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Chronic lymphocytic leukemia</Indication></IndicationsPrimary><ActionsPrimary><Action>PARP modulator</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Exinda Therapeutics is investigating an oral formulation of the nitrogen mustard bendamustine for the potential treatment of chronic lymphocytic leukemia (CLL) [ 1712048 ].</Summary><ActionsSecondary><Action>Anticancer alkylating agent</Action></ActionsSecondary><AddedDate>2015-11-10T00:00:00Z</AddedDate></Drug><Drug id="99811" name="GALE-302" lastModificationDate="2018-01-03T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Galena Biopharma Inc</CompanyOriginator><CompaniesPrimary><Company>SELLAS Life Sciences Group Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Breast tumor</Indication><Indication>Ovary tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>GM-CSF ligand</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Intradermal formulation</Technology><Technology>Peptide</Technology></Technologies><Summary>SELLAS Life Sciences , following its merger with Galena Biopharma, is presumed to be developing GALE-302, a PEPTIDE vaccine consisting of the folate binding protein-variant of E39 (previously named J65) peptide and the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF), for the potential intradermal prevention and treatment of gynecological cancers including ovarian, and breast cancer [ 1711595 ], [ 1511640 ], [ 1994197 ]. In September 2013, a phase Ib/II trial was initiated</Summary><CompaniesSecondary><Company>Galena Biopharma Inc</Company></CompaniesSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Prophylactic vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondary><AddedDate>2015-11-17T00:00:00Z</AddedDate></Drug><Drug id="99769" name="cisplatin (ChemoThin Wafer, oral cancer), Privo Technologies" lastModificationDate="2018-11-02T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Privo Technologies Inc</CompanyOriginator><CompaniesPrimary><Company>Privo Technologies Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Mouth tumor</Indication></IndicationsPrimary><Technologies><Technology>Buccal formulation local</Technology><Technology>Controlled release formulation</Technology><Technology>Nanoparticle formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Privo Technologies is developing PRV-111 presumed to be Cisplatin ChemoThin Wafer, a nano-encapsulated formulation of cisplatin employing the company's CTW nanotechnology platform, for the potential topical and local treatment of pre-malignant and malignant oral cancers [ 1710267 ], [ 1710284 ], [ 1710298 ], [ 2027728 ]. In October 2018, a phase I/II trial in patients with oral cavity squamous cell carcinoma (OCSCC) was initiated [ 2086602 ]. The company is also investigating cisplatin for the</Summary><ActionsSecondary><Action>Anticancer alkylating agent</Action></ActionsSecondary><AddedDate>2015-11-06T00:00:00Z</AddedDate></Drug><Drug id="99758" name="MSS-722" lastModificationDate="2017-08-07T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Veru Inc</CompanyOriginator><CompaniesPrimary><Company>Veru Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Male infertility</Indication></IndicationsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Veru Inc (previosuly Veru Healthcare and (formerly Aspen Park Pharmaceuticals)) is investigating MSS-722 that restores the body's production of testosterone, for the potential oral treatment of male infertility including secondary hypogonadism [ 1699563 ], [ 1947089 ], [ 1947507 ], [ 1950147 ]. In November 2016, the company intended to present an overview of its phase II trial to the US FDA for the development of the drug under a 505(b)(2) regulatory pathway. At that time, the trial was to begin</Summary><IndicationsSecondary><Indication>Male hypogonadism</Indication></IndicationsSecondary><ActionsSecondary><Action>Proceptive</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2015-11-06T00:00:00Z</AddedDate></Drug><Drug id="99754" name="baclofen (intrathecal, spasticity/complex regional pain syndrome), baclofen (intrathecal, spasticity/complex regional pain syndrome), Life Molecular Imaging" lastModificationDate="2018-11-06T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>CNS Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Life Molecular Imaging</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Complex regional pain syndrome</Indication><Indication>Muscle hypertonia</Indication></IndicationsPrimary><ActionsPrimary><Action>GABA B receptor agonist</Action></ActionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Developed and launched by Mallinckrodt (following the acquisition of CNS Therapeutics ) and now marketed by Life Molecular Imaging (formerly Piramal Imaging), Gablofen is an intrathecal formulation of the GABA B agonist baclofen, for the management of severe spasticity of cerebral or spinal origin. The product was approved in the US in November 2010 [ 1149923 ], [ 1328223 ], [ 1709934 ], [ 1909877 ], [ 2073201 ]. By January 2017, Gablofen been approved in eight European countries [ 1896209 ]. The</Summary><CompaniesSecondary><Company>CNS Therapeutics Inc</Company><Company>Mallinckrodt plc</Company></CompaniesSecondary><ActionsSecondary><Action>Analgesic</Action></ActionsSecondary><AddedDate>2015-11-06T00:00:00Z</AddedDate></Drug><Drug id="99753" name="GT-AS" lastModificationDate="2019-05-30T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>University of South Florida</CompanyOriginator><CompaniesPrimary><Company>PTC Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Angelman syndrome</Indication></IndicationsPrimary><ActionsPrimary><Action>UBE3A gene stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>PTC Therapeutics , following the acquisition of Agilis Biotherapeutics (previously under license from University of South Florida ), is investigating GT-AS (previously AGIL-AS), an AAV9-delivered UBE3A gene therapy carrying the gene for E6-AP ubiquitin protein ligase, for the potential treatment of Angelman syndrome (AS) [ 1659532 ], [ 1709864 ], [ 1709856 ], [ 2066347 ], [ 2155084 ]. In May 2015, preclinical studies were ongoing [ 1659532 ]. In October 2017, lead selection was anticipated by the</Summary><CompaniesSecondary><Company>Agilis Biotherapeutics Inc</Company><Company>University of South Florida</Company></CompaniesSecondary><ActionsSecondary><Action>Adeno-associated virus based gene therapy</Action></ActionsSecondary><AddedDate>2015-11-04T00:00:00Z</AddedDate></Drug><Drug id="99727" name="ABCA4 DNA nanoparticles (Stargardt disease), Copernicus Therapeutics" lastModificationDate="2015-11-24T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Copernicus Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Copernicus Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Stargardt disease</Indication></IndicationsPrimary><ActionsPrimary><Action>ABCA4 gene stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Nanoparticle formulation</Technology><Technology>Ophthalmic formulation</Technology><Technology>Polynucleotide sequence</Technology></Technologies><Summary>Copernicus Therapeutics is investigating ABCA4 DNA nanoparticles for the potential treatment of Stargardt macular degeneration [ 1709166 ]. In August 2012, preclinical data were published [ 1709172 ].</Summary><ActionsSecondary><Action>Unspecified non-viral vector based gene therapy</Action></ActionsSecondary><AddedDate>2015-11-04T00:00:00Z</AddedDate></Drug><Drug id="99724" name="P-110 (Alzheimer's disease), Stanford University" lastModificationDate="2017-01-11T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Stanford University</CompanyOriginator><CompaniesPrimary><Company>Stanford University</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Alzheimers disease</Indication><Indication>Huntingtons chorea</Indication></IndicationsPrimary><ActionsPrimary><Action>Mitochondrial fission protein 1 inhibitor</Action></ActionsPrimary><Technologies><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Stanford University is investigating the 20-mer peptide P-110, a dynamin-related protein (Drp) 1/fission (Fis) 1 inhibitor, for the potential treatment of Alzheimer's disease and Huntington's disease [ 1703710 ], [ 1834520 ]. In October 2015, preclinical data were presented [ 1703710 ].</Summary><ActionsSecondary><Action>Neuroprotectant</Action></ActionsSecondary><AddedDate>2015-11-04T00:00:00Z</AddedDate></Drug><Drug id="99721" name="valsartan (oral solution, pediatric hypertension/heart failure/post-myocardial infarction), Medicure" lastModificationDate="2018-10-04T00:00:00Z" phaseHighest="Registered"><CompanyOriginator>Carmel Biosciences</CompanyOriginator><CompaniesPrimary><Company>Medicure Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Cardiac failure</Indication><Indication>Hypertension</Indication></IndicationsPrimary><ActionsPrimary><Action>Angiotensin II receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Medicure under license from Carmel Biosciences , has developed Prexxartan, an oral solution of the angiotensin II antagonist valsartan , for the treatment of hypertension in pediatric patients, heart failure and for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (MI) [ 1709079 ], [ 1976480 ], [ 2077432 ]. In December 2017, the US FDA granted final approval for the drug; at that time</Summary><CompaniesSecondary><Company>Carmel Biosciences</Company></CompaniesSecondary><ActionsSecondary><Action>Antihypertensive</Action></ActionsSecondary><AddedDate>2015-11-03T00:00:00Z</AddedDate></Drug><Drug id="99718" name="H3B-6527" lastModificationDate="2019-01-08T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>H3 Biomedicine Inc</CompanyOriginator><CompaniesPrimary><Company>H3 Biomedicine Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Cholangiocarcinoma</Indication><Indication>Hepatocellular carcinoma</Indication></IndicationsPrimary><ActionsPrimary><Action>FGF4 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Eisai , through its subsidiary H3 Biomedicine , is developing H3B-6527, a lead from a program of FGFR4 inhibitors, for the potential oral treatment of cancer, including advanced hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHCC) [ 1708599 ], [ 1709061 ], [ 1164186 ]. In July 2016, a phase I trial in HCC and IHCC began [ 1781231 ]. At that time, the drug was listed as being in phase I development in the US and Japan [ 1781080 ]. In January 2018, phase Ib combination studies</Summary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondary><AddedDate>2015-11-04T00:00:00Z</AddedDate></Drug><Drug id="9968" name="reviparin sodium" lastModificationDate="2018-08-07T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Knoll GmbH</CompanyOriginator><CompaniesPrimary><Company>Abbott Laboratories</Company><Company>Bausch Health Companies Inc</Company><Company>Knoll GmbH</Company><Company>Mitsui Pharmaceuticals Inc</Company><Company>Schwarz Pharma Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Deep vein thrombosis</Indication><Indication>Lung embolism</Indication><Indication>Tachycardia</Indication><Indication>Thrombosis</Indication></IndicationsPrimary><ActionsPrimary><Action>Low molecular weight heparin</Action></ActionsPrimary><Technologies><Technology>Oligosaccharide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><Summary>Reviparin sodium is a second generation low molecular weight heparin (LMWH) produced by nitrous acid digestion of heparin [ 200634 ], which has been launched by Knoll (now Abbott ) for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) following surgery. It was first launched (as Clivarin) in Germany in 1993 for the prevention to DVT and PE in patients at moderate risk [ 378507 ], [ 430621 ]. It was then launched in May 1995 in France [ 430621 ], however, the drug was withdrawn</Summary><IndicationsSecondary><Indication>Restenosis</Indication></IndicationsSecondary><ActionsSecondary><Action>Antiarrhythmic agent</Action><Action>Coagulation inhibitor</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="99675" name="sirolimus (topical gel formulation, tuberous sclerosis) Nobelpharma" lastModificationDate="2018-08-22T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Osaka University</CompanyOriginator><CompaniesPrimary><Company>Nobelpharma Co Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Sakigake</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Tuberous sclerosis</Indication></IndicationsPrimary><ActionsPrimary><Action>mTOR inhibitor</Action></ActionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Dermatological gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><Summary>NobelPharma , under license from Osaka University , has developed and launched NPC-12G, a topical gel formulation of the immunosuppressive agent sirolimus, for the treatment of angiofibroma in tuberous sclerosis [ 1708073 ], [ 1708260 ], [ 2017598 ]. In March 2018, the drug was approved in Japan [ 2017598 ]; in June 2018, the drug was launched in Japan for the treatment of angiofibroma in patients with tuberous sclerosis [ 2041809 ].</Summary><CompaniesSecondary><Company>Osaka University</Company></CompaniesSecondary><ActionsSecondary><Action>Immunosuppressant</Action><Action>Protein synthesis inhibitor</Action></ActionsSecondary><AddedDate>2015-11-02T00:00:00Z</AddedDate></Drug><Drug id="99610" name="DOT-cells" lastModificationDate="2016-11-26T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Lymphocyte Activation Technologies SA</CompanyOriginator><CompaniesPrimary><Company>GammaDelta Therapeutics Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Chronic lymphocytic leukemia</Indication><Indication>Colon tumor</Indication><Indication>Ovary tumor</Indication><Indication>Pancreas tumor</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>T-lymphocyte</Technology></Technologies><Summary>GammaDelta Therapeutics , following its acquisition of Lymphocyte Activation Technologies (Lymphact), using technology discovered at Instituto de Medicina Molecular , is investigating DOT-cells (Delta One T-cells), an autologous adoptive cell immunotherapy comprising Vdelta1+ T-lymphocytes activated ex vivo by cytokine and mAb treatment, for the potential treatment of leukemia, including chronic lymphocytic leukaemia (CLL), and colon, ovarian and pancreatic cancers [ 1693678 ], [ 1707293</Summary><CompaniesSecondary><Company>Lymphocyte Activation Technologies SA</Company></CompaniesSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Immunostimulant</Action></ActionsSecondary><AddedDate>2015-10-29T00:00:00Z</AddedDate></Drug><Drug id="99570" name="desipramine hydrochloride (Rett syndrome), ORPHELIA Pharma" lastModificationDate="2016-08-31T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>INSERM</CompanyOriginator><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. ORPHELIA Pharma (formerly TargeOn), under license from INSERM , was developing repurposed desipramine hydrochloride (desipramine chlorhydrate; ORP-002), a selective norepinephrine reuptake inhibitor, for the potential oral treatment of respiratory disorders associated with Rett syndrome [ 1706049 ], [ 1715844 ], [ 1715864 ]. A phase II trial began in October 2008 and completed in December 2014 [ 1715852</Summary><CompaniesSecondary><Company>INSERM</Company><Company>ORPHELIA Pharma SA</Company></CompaniesSecondary><IndicationsSecondary><Indication>Rett syndrome</Indication></IndicationsSecondary><ActionsSecondary><Action>Norepinephrine uptake inhibitor</Action><Action>Respiratory system agent</Action></ActionsSecondary><AddedDate>2015-10-26T00:00:00Z</AddedDate></Drug><Drug id="99565" name="AGTC-402" lastModificationDate="2019-06-28T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>AGTC</CompanyOriginator><CompaniesPrimary><Company>AGTC</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Achromatopsia</Indication></IndicationsPrimary><ActionsPrimary><Action>CNGA3 gene stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable formulation</Technology><Technology>Ophthalmic formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>AGTC is developing AGTC-402, a non-replicating, rep/cap deleted, recombinant adeno-associated viral (AAV) vector carrying the CNGA3 gene, administered by subretinal injection, for the potential treatment of achromatopsia caused by mutations in the CNGA3 gene [ 1693678 ], [ 1705775 ], [ 1865518 ]. In May 2017, a phase I/II trial was initiated [ 1865518 ]; In February 2019, topline interim six-month data from the trial were expected in the second half of 2019. At that time, the enrollment of the</Summary><ActionsSecondary><Action>Adeno-associated virus based gene therapy</Action></ActionsSecondary><AddedDate>2015-10-26T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="428" label="&lt; 100"/><FilterOption count="47" label="≥ 100 and  250"/><FilterOption count="41" label="≥ 250 and  500"/><FilterOption count="42" label="≥ 500 and  1000"/><FilterOption count="64" label="≥ 1000"/></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="100"><FilterOption id="1545" count="941" label="Anticancer"/><FilterOption id="2953" count="516" label="Anti-inflammatory"/><FilterOption id="59620" count="264" label="Unspecified drug target"/><FilterOption id="62255" count="237" label="Anticancer protein kinase inhibitor"/><FilterOption id="1615" count="231" label="Neuroprotectant"/><FilterOption id="1589" count="204" label="Apoptosis stimulator"/><FilterOption id="991" count="192" label="Antiviral"/><FilterOption id="55685" count="177" label="Anticancer monoclonal antibody"/><FilterOption id="1596" count="146" label="Immunomodulator"/><FilterOption id="393" count="138" label="Immunostimulant"/><FilterOption id="4781" count="122" label="Adeno-associated virus based gene therapy"/><FilterOption id="61" count="121" label="Angiogenesis inhibitor"/><FilterOption id="7293" count="115" label="Synergist"/><FilterOption id="1594" count="114" label="Antibacterial"/><FilterOption id="396" count="95" label="Immunosuppressant"/><FilterOption id="12379" count="94" label="Therapeutic vaccine"/><FilterOption id="2657" count="93" label="Antihypertensive"/><FilterOption id="7761" count="83" label="T-lymphocyte stimulator"/><FilterOption id="15128" count="82" label="Ophthalmological agent"/><FilterOption id="2946" count="81" label="Analgesic"/><FilterOption id="70" count="70" label="Anticonvulsant agent"/><FilterOption id="767" count="69" label="Cell cycle inhibitor"/><FilterOption id="399" count="67" label="Hypoglycemic agent"/><FilterOption id="2947" count="66" label="Antiparkinsonian"/><FilterOption id="664" count="64" label="Fibrosuppressant"/><FilterOption id="1470" count="61" label="Respiratory system agent"/><FilterOption id="7220" count="53" label="Neoplasm diagnostic agent"/><FilterOption id="4790" count="51" label="Genetically engineered autologous cell therapy"/><FilterOption id="284" count="50" label="Nootropic agent"/><FilterOption id="15184" count="50" label="Systemic antipsoriatic product"/><FilterOption id="2638" count="48" label="Antiparasitic"/><FilterOption id="50" count="47" label="Anticancer alkylating agent"/><FilterOption id="1748" count="43" label="Fungicide"/><FilterOption id="968" count="39" label="Coagulation stimulator"/><FilterOption id="539" count="39" label="Immunotoxin"/><FilterOption id="74" count="38" label="Antioxidant agent"/><FilterOption id="7294" count="38" label="Antisense oligonucleotide inhibitor"/><FilterOption id="1408" count="38" label="Muscle system agent"/><FilterOption id="388" count="38" label="Vasodilator"/><FilterOption id="1590" count="37" label="Apoptosis inhibitor"/><FilterOption id="7292" count="37" label="Vulnerary agent"/><FilterOption id="2941" count="35" label="Antidepressant"/><FilterOption id="140" count="34" label="DNA synthesis inhibitor"/><FilterOption id="2659" count="30" label="Cardioprotectant"/><FilterOption id="750" count="29" label="DNA intercalator"/><FilterOption id="1332" count="29" label="Gastrointestinal system agent"/><FilterOption id="610" count="28" label="Hematopoietic stimulator"/><FilterOption id="7212" count="27" label="Endocrine diagnostic agent"/><FilterOption id="2939" count="26" label="CNS modulator"/><FilterOption id="4155" count="26" label="Imaging agent"/><FilterOption id="2575" count="26" label="Microtubule inhibitor"/><FilterOption id="695" count="25" label="Metastasis inhibitor"/><FilterOption id="55684" count="24" label="Anticancer antibody"/><FilterOption id="2943" count="24" label="Antipsychotic"/><FilterOption id="12378" count="23" label="Prophylactic vaccine"/><FilterOption id="1569" count="22" label="Anticancer antimetabolite"/><FilterOption id="1546" count="22" label="Blood system agent"/><FilterOption id="5720" count="22" label="Radiodiagnostic"/><FilterOption id="1465" count="22" label="Radioprotectant"/><FilterOption id="26035" count="22" label="siRNA agent"/><FilterOption id="659" count="21" label="Coagulation inhibitor"/><FilterOption id="4780" count="20" label="Adenovirus based gene therapy"/><FilterOption id="1880" count="19" label="Dermatological agent"/><FilterOption id="7213" count="19" label="Gastrointestinal diagnostic agent"/><FilterOption id="2576" count="19" label="Microtubule stabilizer"/><FilterOption id="5555" count="19" label="PET contrast agent"/><FilterOption id="312" count="19" label="Platelet aggregation inhibitor"/><FilterOption id="959" count="19" label="Protectant"/><FilterOption id="524" count="18" label="Adjuvant"/><FilterOption id="7243" count="18" label="Antidote"/><FilterOption id="3272" count="18" label="Growth hormone release inhibitor"/><FilterOption id="339" count="18" label="Protein synthesis inhibitor"/><FilterOption id="2660" count="18" label="Vasoprotectant"/><FilterOption id="62253" count="17" label="Anticancer hormone"/><FilterOption id="1389" count="17" label="Lipid metabolism modulator"/><FilterOption id="1552" count="17" label="Radioimmunotherapeutic"/><FilterOption id="4782" count="17" label="Retrovirus based gene therapy"/><FilterOption id="7018" count="16" label="Antihypertriglyceridemic agent"/><FilterOption id="102926" count="16" label="Dendritic cell vaccine"/><FilterOption id="1467" count="16" label="Renal system agent"/><FilterOption id="1532" count="16" label="Viral replication inhibitor"/><FilterOption id="71" count="15" label="Antihypercholesterolemic agent"/><FilterOption id="5721" count="15" label="Radiotherapeutic"/><FilterOption id="2954" count="15" label="Steroidal anti-inflammatory"/><FilterOption id="1610" count="15" label="Surfactant"/><FilterOption id="2942" count="14" label="Anxiolytic"/><FilterOption id="89" count="14" label="Bone resorption inhibitor"/><FilterOption id="965" count="14" label="Cardiovascular agent"/><FilterOption id="105" count="14" label="Chelating agent"/><FilterOption id="2955" count="14" label="Non-steroidal anti-inflammatory"/><FilterOption id="12372" count="14" label="Protein subunit vaccine"/><FilterOption id="1542" count="14" label="Radiosensitizer"/><FilterOption id="53558" count="14" label="Stem cell modulator"/><FilterOption id="2667" count="13" label="Antiarteriosclerotic"/><FilterOption id="7751" count="13" label="Macrophage stimulator"/><FilterOption id="173474" count="13" label="Microbiome modulator"/><FilterOption id="7757" count="13" label="Natural killer cell stimulator"/><FilterOption id="799" count="13" label="Photosensitizer"/><FilterOption id="4405" count="13" label="Radioimmunodiagnostic"/><FilterOption id="62" count="12" label="Angiogenesis stimulator"/></Filter><Filter label="Drug Deal Types" name="drugDealTypes" total="20"><FilterOption id="4" count="1321" label="Drug - Development/Commercialization License"/><FilterOption id="13" count="793" label="Drug - Funding"/><FilterOption id="6" count="567" label="Drug - Manufacturing/Supply"/><FilterOption id="3" count="560" label="Drug - Early Research/Development"/><FilterOption id="7" count="539" label="Drug - Development Services"/><FilterOption id="5" count="439" label="Drug - Commercialization License"/><FilterOption id="10" count="290" label="Technology - Other Proprietary"/><FilterOption id="11" count="275" label="Patent - Exclusive Rights"/><FilterOption id="2" count="219" label="Drug - Screening/Evaluation"/><FilterOption id="14" count="179" label="Drug - Asset Divestment"/><FilterOption id="8" count="129" label="Technology - Delivery/Formulation"/><FilterOption id="15" count="94" label="Drug - CRADA"/><FilterOption id="20" count="72" label="Company - M&amp;A (in whole or part)"/><FilterOption id="12" count="59" label="Patent - Non-Exclusive Rights"/><FilterOption id="1" count="41" label="Drug - Discovery/Design"/><FilterOption id="19" count="30" label="Company - Joint Venture"/><FilterOption id="21" count="15" label="Patent - Litigation Settlement"/><FilterOption id="16" count="10" label="Technology - Asset Divestment"/><FilterOption id="17" count="8" label="Patent - Asset Divestment"/><FilterOption id="9" count="4" label="Technology - Target Validation"/></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="242" label="&lt; 100"/><FilterOption count="67" label="≥ 100 and  250"/><FilterOption count="66" label="≥ 250 and  500"/><FilterOption count="50" label="≥ 500 and  1000"/><FilterOption count="81" label="≥ 1000"/></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="887" label="= 0"/><FilterOption count="672" label="&gt; 1 and ≤ 1"/><FilterOption count="488" label="&gt; 2 and ≤ 2"/><FilterOption count="349" label="&gt; 3 and ≤ 3"/><FilterOption count="248" label="&gt; 4 and ≤ 4"/><FilterOption count="132" label="&gt; 5 and ≤ 5"/><FilterOption count="337" label="&gt; 6 and ≤ 10"/><FilterOption count="118" label="&gt; 11"/></Filter><Filter label="Technologies" name="technologies" total="100"><FilterOption id="762" count="1741" label="Small molecule therapeutic"/><FilterOption id="761" count="1434" label="Biological therapeutic"/><FilterOption id="585" count="975" label="Oral formulation"/><FilterOption id="648" count="957" label="Intravenous formulation"/><FilterOption id="740" count="598" label="Infusion"/><FilterOption id="595" count="330" label="Tablet formulation"/><FilterOption id="766" count="286" label="Parenteral formulation unspecified"/><FilterOption id="647" count="286" label="Subcutaneous formulation"/><FilterOption id="85" count="285" label="Protein recombinant"/><FilterOption id="586" count="282" label="Capsule formulation"/><FilterOption id="80" count="264" label="Peptide"/><FilterOption id="573" count="183" label="Immunoglobulin-G"/><FilterOption id="62" count="173" label="Virus recombinant"/><FilterOption id="746" count="147" label="Solution"/><FilterOption id="1263" count="145" label="Immuno-oncology"/><FilterOption id="169" count="144" label="Monoclonal antibody humanized"/><FilterOption id="616" count="105" label="Inhalant formulation"/><FilterOption id="603" count="103" label="Systemic formulation unspecified"/><FilterOption id="175" count="102" label="Drug combination"/><FilterOption id="898" count="98" label="Formulation powder"/><FilterOption id="168" count="97" label="Monoclonal antibody human"/><FilterOption id="589" count="97" label="Sustained release formulation"/><FilterOption id="84" count="96" label="Protein fusion"/><FilterOption id="1647" count="95" label="Natural product"/><FilterOption id="651" count="92" label="Intramuscular formulation"/><FilterOption id="751" count="90" label="Film coating"/><FilterOption id="750" count="89" label="Freeze drying"/><FilterOption id="1652" count="84" label="Prodrug"/><FilterOption id="620" count="83" label="Ophthalmic formulation"/><FilterOption id="596" count="80" label="Injectable formulation"/><FilterOption id="570" count="72" label="Cell therapy"/><FilterOption id="901" count="70" label="Recombinant enzyme"/><FilterOption id="611" count="66" label="Dermatological formulation"/><FilterOption id="66" count="62" label="Antibiotic"/><FilterOption id="593" count="60" label="Oral liquid formulation"/><FilterOption id="594" count="59" label="Oral suspension formulation"/><FilterOption id="103" count="53" label="Oligonucleotide"/><FilterOption id="569" count="52" label="Oligonucleotide antisense"/><FilterOption id="180" count="49" label="Antibody fragment"/><FilterOption id="731" count="48" label="Imaging"/><FilterOption id="347" count="47" label="Intratumoral formulation"/><FilterOption id="171" count="47" label="Monoclonal antibody conjugated"/><FilterOption id="617" count="46" label="Aerosol formulation inhalant"/><FilterOption id="599" count="46" label="Nanoparticle formulation injectable"/><FilterOption id="348" count="46" label="PEGylated formulation"/><FilterOption id="724" count="45" label="Radiolabeling"/><FilterOption id="856" count="43" label="Autologous stem cell therapy"/><FilterOption id="142" count="41" label="Liposome formulation"/><FilterOption id="135" count="40" label="T-lymphocyte"/><FilterOption id="884" count="37" label="Haematopoietic stem cell therapy"/><FilterOption id="851" count="36" label="Intradermal formulation"/><FilterOption id="654" count="34" label="Intrathecal formulation"/><FilterOption id="166" count="33" label="Chimeric monoclonal antibody"/><FilterOption id="582" count="32" label="Antibody polyclonal"/><FilterOption id="74" count="32" label="Glycoprotein"/><FilterOption id="745" count="32" label="Suspension"/><FilterOption id="558" count="32" label="Transdermal formulation"/><FilterOption id="1668" count="31" label="Nanoparticle formulation"/><FilterOption id="641" count="29" label="Controlled release formulation"/><FilterOption id="894" count="29" label="Liquid formulation"/><FilterOption id="857" count="28" label="Allogenic stem cell therapy"/><FilterOption id="90" count="28" label="Steroid"/><FilterOption id="349" count="27" label="Lipid"/><FilterOption id="207" count="25" label="Protein conjugated"/><FilterOption id="764" count="23" label="Local formulation unspecified"/><FilterOption id="805" count="22" label="Daily dosing"/><FilterOption id="4" count="22" label="Immunoglobulin"/><FilterOption id="51" count="22" label="Monoclonal antibody"/><FilterOption id="660" count="22" label="Oral sustained release formulation"/><FilterOption id="93" count="22" label="Toxin"/><FilterOption id="864" count="21" label="Mesenchymal stem cell therapy"/><FilterOption id="659" count="21" label="Ophthalmic liquid formulation"/><FilterOption id="618" count="21" label="Powder formulation inhalant"/><FilterOption id="1651" count="19" label="Blood constituents"/><FilterOption id="775" count="19" label="Dermatological gel formulation"/><FilterOption id="743" count="19" label="Granule"/><FilterOption id="1247" count="18" label="Chimeric antigen receptor T cell therapy"/><FilterOption id="1646" count="18" label="Injectable controlled release formulation"/><FilterOption id="102" count="18" label="Nucleotide and derivatives"/><FilterOption id="345" count="18" label="Receptor chimeric"/><FilterOption id="216" count="17" label="Antibody conjugated"/><FilterOption id="72" count="17" label="Enzyme"/><FilterOption id="159" count="17" label="Oligosaccharide"/><FilterOption id="559" count="16" label="Oral controlled release formulation"/><FilterOption id="1164" count="15" label="Antibody drug conjugate"/><FilterOption id="612" count="15" label="Emulsion dermatological"/><FilterOption id="1669" count="15" label="Emulsion formulation"/><FilterOption id="1653" count="15" label="Tumor antigen"/><FilterOption id="680" count="14" label="Buccal formulation systemic"/><FilterOption id="1656" count="14" label="CNS formulation"/><FilterOption id="590" count="14" label="Enteric coated formulation"/><FilterOption id="649" count="14" label="Intraperitoneal formulation"/><FilterOption id="167" count="14" label="Monoclonal antibody murine"/><FilterOption id="170" count="14" label="Multivalent monoclonal antibody"/><FilterOption id="598" count="13" label="Liposome formulation injectable"/><FilterOption id="753" count="13" label="Microparticle formulation"/><FilterOption id="605" count="13" label="Nasal systemic formulation"/><FilterOption id="667" count="13" label="Peptidomimetic"/><FilterOption id="94" count="13" label="RNA antisense"/><FilterOption id="128" count="12" label="Cell culture technique"/></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="100"><FilterOption count="422" label="1996-02-16"/><FilterOption count="20" label="2016-10-27"/><FilterOption count="18" label="2015-08-01"/><FilterOption count="10" label="2015-05-14"/><FilterOption count="10" label="2015-10-22"/><FilterOption count="10" label="2016-11-26"/><FilterOption count="10" label="2019-01-08"/><FilterOption count="9" label="2014-09-18"/><FilterOption count="9" label="2015-04-29"/><FilterOption count="8" label="2013-10-18"/><FilterOption count="8" label="2014-04-09"/><FilterOption count="8" label="2015-05-13"/><FilterOption count="8" label="2016-05-04"/><FilterOption count="7" label="2013-10-30"/><FilterOption count="7" label="2016-08-31"/><FilterOption count="6" label="2004-12-06"/><FilterOption count="6" label="2015-01-09"/><FilterOption count="6" label="2016-06-08"/><FilterOption count="6" label="2016-10-24"/><FilterOption count="6" label="2017-11-06"/><FilterOption count="5" label="2006-12-12"/><FilterOption count="5" label="2011-09-14"/><FilterOption count="5" label="2014-12-06"/><FilterOption count="5" label="2015-09-09"/><FilterOption count="4" label="1998-06-08"/><FilterOption count="4" label="2002-01-11"/><FilterOption count="4" label="2007-01-30"/><FilterOption count="4" label="2009-10-27"/><FilterOption count="4" label="2011-01-12"/><FilterOption count="4" label="2011-04-08"/><FilterOption count="4" label="2011-06-07"/><FilterOption count="4" label="2012-02-23"/><FilterOption count="4" label="2012-06-20"/><FilterOption count="4" label="2012-09-21"/><FilterOption count="4" label="2013-07-19"/><FilterOption count="4" label="2016-02-17"/><FilterOption count="4" label="2016-05-23"/><FilterOption count="4" label="2016-12-07"/><FilterOption count="4" label="2016-12-20"/><FilterOption count="4" label="2017-04-27"/><FilterOption count="4" label="2017-07-08"/><FilterOption count="4" label="2017-09-22"/><FilterOption count="4" label="2017-09-26"/><FilterOption count="3" label="1996-04-19"/><FilterOption count="3" label="1996-08-15"/><FilterOption count="3" label="1996-08-19"/><FilterOption count="3" label="2002-07-22"/><FilterOption count="3" label="2003-03-20"/><FilterOption count="3" label="2003-03-24"/><FilterOption count="3" label="2003-03-26"/><FilterOption count="3" label="2003-11-21"/><FilterOption count="3" label="2005-05-19"/><FilterOption count="3" label="2005-09-30"/><FilterOption count="3" label="2005-11-21"/><FilterOption count="3" label="2007-01-18"/><FilterOption count="3" label="2007-09-21"/><FilterOption count="3" label="2008-04-23"/><FilterOption count="3" label="2008-07-14"/><FilterOption count="3" label="2008-12-15"/><FilterOption count="3" label="2009-01-14"/><FilterOption count="3" label="2009-04-28"/><FilterOption count="3" label="2009-06-16"/><FilterOption count="3" label="2010-03-10"/><FilterOption count="3" label="2011-09-06"/><FilterOption count="3" label="2011-11-19"/><FilterOption count="3" label="2011-11-26"/><FilterOption count="3" label="2012-01-07"/><FilterOption count="3" label="2012-01-28"/><FilterOption count="3" label="2012-05-02"/><FilterOption count="3" label="2012-07-17"/><FilterOption count="3" label="2013-11-13"/><FilterOption count="3" label="2013-12-17"/><FilterOption count="3" label="2014-12-16"/><FilterOption count="3" label="2015-05-20"/><FilterOption count="3" label="2015-09-13"/><FilterOption count="3" label="2015-11-04"/><FilterOption count="3" label="2015-11-17"/><FilterOption count="3" label="2015-12-08"/><FilterOption count="3" label="2016-01-11"/><FilterOption count="3" label="2016-03-04"/><FilterOption count="3" label="2016-04-04"/><FilterOption count="3" label="2016-07-05"/><FilterOption count="3" label="2016-07-15"/><FilterOption count="3" label="2016-08-13"/><FilterOption count="3" label="2017-01-11"/><FilterOption count="3" label="2017-02-13"/><FilterOption count="3" label="2017-03-09"/><FilterOption count="3" label="2017-05-29"/><FilterOption count="3" label="2017-06-03"/><FilterOption count="3" label="2017-06-09"/><FilterOption count="3" label="2017-08-21"/><FilterOption count="3" label="2017-08-23"/><FilterOption count="3" label="2017-11-10"/><FilterOption count="3" label="2017-12-21"/><FilterOption count="2" label="1996-05-23"/><FilterOption count="2" label="1996-09-04"/><FilterOption count="2" label="1996-09-13"/><FilterOption count="2" label="1996-11-07"/><FilterOption count="2" label="1996-11-19"/><FilterOption count="2" label="1997-04-09"/></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="2"><FilterOption count="2636" label="No"/><FilterOption count="595" label="Yes"/></Filter><Filter label="Secondary Companies" name="companiesSecondary" total="100"><FilterOption id="18767" count="42" label="Pfizer Inc"/><FilterOption id="28355" count="39" label="GlaxoSmithKline plc"/><FilterOption id="23137" count="36" label="Novartis AG"/><FilterOption id="13601" count="34" label="Abbott Laboratories"/><FilterOption id="15065" count="25" label="Bristol-Myers Squibb Co"/><FilterOption id="19453" count="25" label="Genentech Inc"/><FilterOption id="14109" count="22" label="Amgen Inc"/><FilterOption id="1109518" count="22" label="Baxalta Inc"/><FilterOption id="14437" count="21" label="Baxter International Inc"/><FilterOption id="18077" count="21" label="Merck &amp; Co Inc"/><FilterOption id="17810" count="20" label="Eli Lilly &amp; Co"/><FilterOption id="19711" count="20" label="Schering-Plough Corp"/><FilterOption id="24652" count="20" label="Shire plc"/><FilterOption id="16299" count="19" label="Sanofi Genzyme"/><FilterOption id="19446" count="17" label="Roche Holding AG"/><FilterOption id="14190" count="16" label="AstraZeneca plc"/><FilterOption id="19687" count="16" label="Bayer Schering Pharma AG"/><FilterOption id="1005244" count="15" label="Biogen Inc"/><FilterOption id="15414" count="15" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="18008" count="15" label="MedImmune LLC"/><FilterOption id="1009547" count="15" label="Sanofi SA"/><FilterOption id="20300" count="15" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="1013295" count="14" label="Astellas Pharma Inc"/><FilterOption id="16453" count="14" label="Glaxo Group Ltd"/><FilterOption id="17332" count="14" label="Johnson &amp; Johnson"/><FilterOption id="22122" count="14" label="Memorial Sloan-Kettering Cancer Center"/><FilterOption id="19862" count="14" label="Merck Serono SA"/><FilterOption id="20519" count="14" label="National Cancer Institute"/><FilterOption id="27638" count="14" label="Pharmacia Corp"/><FilterOption id="21159" count="14" label="Sigma-Tau Ind Farm Riunite SpA"/><FilterOption id="24236" count="13" label="Cambridge Antibody Technology Group plc"/><FilterOption id="15385" count="13" label="Chiron Corp"/><FilterOption id="20518" count="13" label="National Institutes of Health"/><FilterOption id="20348" count="13" label="Teva Pharmaceutical Industries Ltd"/><FilterOption id="15872" count="12" label="Eisai Co Ltd"/><FilterOption id="17269" count="12" label="Ionis Pharmaceuticals Inc"/><FilterOption id="26997" count="12" label="Janssen Biotech Inc"/><FilterOption id="22006" count="12" label="Pharmacia &amp; Upjohn Inc"/><FilterOption id="23780" count="11" label="Actelion Ltd"/><FilterOption id="21885" count="11" label="Astex Pharmaceuticals Inc"/><FilterOption id="25218" count="11" label="Aventis Pharma AG"/><FilterOption id="14455" count="11" label="Bayer AG"/><FilterOption id="25224" count="11" label="Hoechst Marion Roussel Inc"/><FilterOption id="17661" count="11" label="Kirin Brewery Co Ltd"/><FilterOption id="17724" count="11" label="Kyowa Hakko Kogyo Co Ltd"/><FilterOption id="1072507" count="10" label="AbbVie Inc"/><FilterOption id="15873" count="10" label="Elan Corp plc"/><FilterOption id="16045" count="10" label="Enzon Pharmaceuticals Inc"/><FilterOption id="16227" count="10" label="Fujisawa Pharmaceutical Co Ltd"/><FilterOption id="17808" count="10" label="Ligand Pharmaceuticals Inc"/><FilterOption id="23382" count="10" label="MD Anderson Cancer Center"/><FilterOption id="19962" count="10" label="SmithKline Beecham plc"/><FilterOption id="14911" count="10" label="Sumitomo Pharmaceuticals Co Ltd"/><FilterOption id="25861" count="9" label="BioMarin Pharmaceutical Inc"/><FilterOption id="15331" count="9" label="Celgene Corp"/><FilterOption id="26178" count="9" label="F Hoffmann-La Roche AG"/><FilterOption id="17327" count="9" label="Japan Tobacco Inc"/><FilterOption id="25902" count="8" label="Array BioPharma Inc"/><FilterOption id="14729" count="8" label="Biogen Inc (FL)"/><FilterOption id="1011990" count="8" label="Emergent BioSolutions Inc"/><FilterOption id="16450" count="8" label="Gilead Sciences Inc"/><FilterOption id="17259" count="8" label="Ipsen"/><FilterOption id="17968" count="8" label="Medarex Inc"/><FilterOption id="27477" count="8" label="Paladin Labs Inc"/><FilterOption id="19162" count="8" label="PDL BioPharma Inc"/><FilterOption id="20679" count="8" label="Stanford University"/><FilterOption id="20623" count="8" label="University of Michigan"/><FilterOption id="14112" count="8" label="Wyeth"/><FilterOption id="17058" count="7" label="Bausch Health Companies Inc"/><FilterOption id="15266" count="7" label="BTG plc"/><FilterOption id="17229" count="7" label="INSERM"/><FilterOption id="1039991" count="7" label="Nationwide Children's Hospital"/><FilterOption id="20592" count="7" label="University of Illinois"/><FilterOption id="20954" count="7" label="XOMA Corp"/><FilterOption id="1153354" count="6" label="Alfasigma SpA"/><FilterOption id="15623" count="6" label="ASTA Medica AG"/><FilterOption id="14881" count="6" label="Boehringer Ingelheim International GmbH"/><FilterOption id="15358" count="6" label="Cephalon Inc"/><FilterOption id="20559" count="6" label="Columbia University"/><FilterOption id="18101" count="6" label="Merck KGaA"/><FilterOption id="18203" count="6" label="MGI Pharma Inc"/><FilterOption id="21102" count="6" label="Scripps Research Institute"/><FilterOption id="20436" count="6" label="Shire Human Genetic Therapies Inc"/><FilterOption id="1002503" count="6" label="Takeda Pharmaceuticals International GmbH"/><FilterOption id="25439" count="6" label="United Therapeutics Corp"/><FilterOption id="26488" count="5" label="Agouron Pharmaceuticals Inc"/><FilterOption id="14042" count="5" label="Allergan Inc"/><FilterOption id="27235" count="5" label="Amsterdam Molecular Therapeutics BV"/><FilterOption id="14239" count="5" label="Antisoma plc"/><FilterOption id="15585" count="5" label="CytRx Corp"/><FilterOption id="20567" count="5" label="Duke University"/><FilterOption id="23744" count="5" label="ILEX Oncology Inc"/><FilterOption id="20631" count="5" label="Mount Sinai School of Medicine"/><FilterOption id="14845" count="5" label="Savient Pharmaceuticals Inc"/><FilterOption id="25451" count="5" label="University of California San Diego"/><FilterOption id="20739" count="5" label="Vertex Pharmaceuticals Inc"/><FilterOption id="20787" count="5" label="Warner-Lambert Co"/><FilterOption id="21717" count="4" label="Actavis Inc"/><FilterOption id="13794" count="4" label="Ajinomoto Co Inc"/><FilterOption id="13979" count="4" label="Alexion Pharmaceuticals Inc"/></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="100"><FilterOption id="651" count="141" label="Cancer"/><FilterOption id="1731" count="127" label="Acute myelogenous leukemia"/><FilterOption id="725" count="126" label="Solid tumor"/><FilterOption id="49" count="113" label="Breast tumor"/><FilterOption id="799" count="108" label="Ovary tumor"/><FilterOption id="2454" count="106" label="Glioblastoma"/><FilterOption id="1828" count="102" label="Multiple myeloma"/><FilterOption id="249" count="99" label="Pancreas tumor"/><FilterOption id="1262" count="95" label="Non-small-cell lung cancer"/><FilterOption id="3657" count="88" label="Metastatic breast cancer"/><FilterOption id="1767" count="81" label="Hepatocellular carcinoma"/><FilterOption id="319" count="79" label="Non-Hodgkin lymphoma"/><FilterOption id="3713" count="77" label="Advanced solid tumor"/><FilterOption id="1108" count="72" label="Glioma"/><FilterOption id="3665" count="71" label="Metastatic non small cell lung cancer"/><FilterOption id="1272" count="70" label="Myelodysplastic syndrome"/><FilterOption id="1734" count="67" label="Chronic lymphocytic leukemia"/><FilterOption id="212" count="64" label="Motor neurone disease"/><FilterOption id="1749" count="62" label="Diffuse large B-cell lymphoma"/><FilterOption id="88" count="59" label="Cystic fibrosis"/><FilterOption id="989" count="56" label="Colorectal tumor"/><FilterOption id="205" count="55" label="Melanoma"/><FilterOption id="3658" count="54" label="Metastatic colorectal cancer"/><FilterOption id="3669" count="51" label="Metastatic pancreas cancer"/><FilterOption id="3257" count="51" label="Stage IV melanoma"/><FilterOption id="213" count="50" label="Multiple sclerosis"/><FilterOption id="623" count="49" label="Head and neck tumor"/><FilterOption id="14" count="48" label="Alzheimers disease"/><FilterOption id="616" count="45" label="Graft versus host disease"/><FilterOption id="1728" count="43" label="Acute lymphoblastic leukemia"/><FilterOption id="1128" count="43" label="Neuroendocrine tumor"/><FilterOption id="2020" count="42" label="Duchenne dystrophy"/><FilterOption id="3378" count="42" label="Soft tissue sarcoma"/><FilterOption id="1745" count="41" label="Follicle center lymphoma"/><FilterOption id="2054" count="41" label="Hematological neoplasm"/><FilterOption id="3771" count="40" label="Idiopathic pulmonary fibrosis"/><FilterOption id="3510" count="40" label="Pulmonary artery hypertension"/><FilterOption id="1261" count="40" label="Small-cell lung cancer"/><FilterOption id="1765" count="39" label="Cholangiocarcinoma"/><FilterOption id="203" count="39" label="Lymphoma"/><FilterOption id="4250" count="39" label="Metastatic renal cell carcinoma"/><FilterOption id="255" count="39" label="Parkinsons disease"/><FilterOption id="276" count="39" label="Prostate tumor"/><FilterOption id="1766" count="39" label="Renal cell carcinoma"/><FilterOption id="127" count="39" label="Stomach tumor"/><FilterOption id="337" count="37" label="Ulcerative colitis"/><FilterOption id="2380" count="34" label="Bladder cancer"/><FilterOption id="1240" count="34" label="Mesothelioma"/><FilterOption id="2726" count="34" label="Neuroblastoma"/><FilterOption id="291" count="34" label="Rheumatoid arthritis"/><FilterOption id="307" count="34" label="Squamous cell carcinoma"/><FilterOption id="1705" count="32" label="Endometrioid carcinoma"/><FilterOption id="119" count="31" label="Epilepsy"/><FilterOption id="3246" count="31" label="Hormone refractory prostate cancer"/><FilterOption id="2637" count="31" label="Non-alcoholic steatohepatitis"/><FilterOption id="1753" count="31" label="Peripheral T-cell lymphoma"/><FilterOption id="1754" count="30" label="Cutaneous T-cell lymphoma"/><FilterOption id="1735" count="29" label="Chronic myelocytic leukemia"/><FilterOption id="121" count="29" label="Factor VIII deficiency"/><FilterOption id="3083" count="29" label="Peritoneal tumor"/><FilterOption id="1011" count="28" label="Esophagus tumor"/><FilterOption id="170" count="28" label="Huntingtons chorea"/><FilterOption id="1105" count="28" label="Scleroderma"/><FilterOption id="1185" count="27" label="Chronic obstructive pulmonary disease"/><FilterOption id="84" count="27" label="Crohns disease"/><FilterOption id="755" count="27" label="Lung tumor"/><FilterOption id="367" count="27" label="Radiation sickness"/><FilterOption id="2004" count="27" label="Retinitis pigmentosa"/><FilterOption id="1771" count="27" label="Transitional cell carcinoma"/><FilterOption id="31" count="26" label="Asthma"/><FilterOption id="2243" count="26" label="Fallopian tube cancer"/><FilterOption id="3466" count="26" label="Metastatic bladder cancer"/><FilterOption id="303" count="26" label="Sickle cell anemia"/><FilterOption id="1516" count="25" label="Biliary cancer"/><FilterOption id="158" count="25" label="HIV infection"/><FilterOption id="1744" count="25" label="Mantle cell lymphoma"/><FilterOption id="427" count="25" label="Uterine cervix tumor"/><FilterOption id="2436" count="24" label="Myelofibrosis"/><FilterOption id="36" count="23" label="Autoimmune disease"/><FilterOption id="3666" count="23" label="Metastatic stomach cancer"/><FilterOption id="159" count="22" label="HIV-1 infection"/><FilterOption id="65" count="22" label="Stroke"/><FilterOption id="316" count="21" label="B-cell lymphoma"/><FilterOption id="3673" count="21" label="Metastatic head and neck cancer"/><FilterOption id="161" count="20" label="Hodgkins disease"/><FilterOption id="848" count="20" label="Myasthenia gravis"/><FilterOption id="281" count="20" label="Psoriasis"/><FilterOption id="1228" count="19" label="Factor IX deficiency"/><FilterOption id="3866" count="19" label="Metastatic ovary cancer"/><FilterOption id="2975" count="18" label="Ewing sarcoma"/><FilterOption id="152" count="18" label="Hepatitis B virus infection"/><FilterOption id="280" count="18" label="Pseudomonas aeruginosa infection"/><FilterOption id="3256" count="18" label="Stage III melanoma"/><FilterOption id="760" count="17" label="Brain tumor"/><FilterOption id="124" count="17" label="Fungal infection"/><FilterOption id="221" count="17" label="Mycobacterium tuberculosis infection"/><FilterOption id="20" count="17" label="Pain"/><FilterOption id="341" count="17" label="Uveitis"/><FilterOption id="123" count="16" label="Fragile X syndrome"/><FilterOption id="188" count="16" label="Inflammatory disease"/></Filter><Filter label="Secondary Indications" name="indicationsSecondary" total="100"><FilterOption id="651" count="446" label="Cancer"/><FilterOption id="725" count="220" label="Solid tumor"/><FilterOption id="49" count="125" label="Breast tumor"/><FilterOption id="799" count="113" label="Ovary tumor"/><FilterOption id="1262" count="108" label="Non-small-cell lung cancer"/><FilterOption id="205" count="105" label="Melanoma"/><FilterOption id="989" count="103" label="Colorectal tumor"/><FilterOption id="249" count="101" label="Pancreas tumor"/><FilterOption id="188" count="86" label="Inflammatory disease"/><FilterOption id="1828" count="86" label="Multiple myeloma"/><FilterOption id="291" count="80" label="Rheumatoid arthritis"/><FilterOption id="1731" count="73" label="Acute myelogenous leukemia"/><FilterOption id="276" count="73" label="Prostate tumor"/><FilterOption id="319" count="63" label="Non-Hodgkin lymphoma"/><FilterOption id="3246" count="59" label="Hormone refractory prostate cancer"/><FilterOption id="755" count="59" label="Lung tumor"/><FilterOption id="1272" count="59" label="Myelodysplastic syndrome"/><FilterOption id="213" count="57" label="Multiple sclerosis"/><FilterOption id="1108" count="56" label="Glioma"/><FilterOption id="623" count="52" label="Head and neck tumor"/><FilterOption id="1734" count="51" label="Chronic lymphocytic leukemia"/><FilterOption id="36" count="50" label="Autoimmune disease"/><FilterOption id="1261" count="49" label="Small-cell lung cancer"/><FilterOption id="281" count="48" label="Psoriasis"/><FilterOption id="2054" count="47" label="Hematological neoplasm"/><FilterOption id="2454" count="46" label="Glioblastoma"/><FilterOption id="4250" count="45" label="Metastatic renal cell carcinoma"/><FilterOption id="1767" count="42" label="Hepatocellular carcinoma"/><FilterOption id="194" count="42" label="Sarcoma"/><FilterOption id="88" count="41" label="Cystic fibrosis"/><FilterOption id="199" count="41" label="Leukemia"/><FilterOption id="3713" count="40" label="Advanced solid tumor"/><FilterOption id="84" count="40" label="Crohns disease"/><FilterOption id="65" count="39" label="Stroke"/><FilterOption id="31" count="38" label="Asthma"/><FilterOption id="14" count="37" label="Alzheimers disease"/><FilterOption id="158" count="37" label="HIV infection"/><FilterOption id="760" count="36" label="Brain tumor"/><FilterOption id="203" count="36" label="Lymphoma"/><FilterOption id="1766" count="35" label="Renal cell carcinoma"/><FilterOption id="515" count="35" label="Transplant rejection"/><FilterOption id="127" count="33" label="Stomach tumor"/><FilterOption id="255" count="31" label="Parkinsons disease"/><FilterOption id="1185" count="30" label="Chronic obstructive pulmonary disease"/><FilterOption id="767" count="30" label="Colon tumor"/><FilterOption id="189" count="30" label="Inflammatory bowel disease"/><FilterOption id="3257" count="30" label="Stage IV melanoma"/><FilterOption id="316" count="29" label="B-cell lymphoma"/><FilterOption id="616" count="28" label="Graft versus host disease"/><FilterOption id="837" count="28" label="Non-insulin dependent diabetes"/><FilterOption id="318" count="28" label="Systemic lupus erythematosus"/><FilterOption id="337" count="28" label="Ulcerative colitis"/><FilterOption id="836" count="27" label="Insulin dependent diabetes"/><FilterOption id="202" count="27" label="Liver tumor"/><FilterOption id="1226" count="26" label="Age related macular degeneration"/><FilterOption id="3665" count="26" label="Metastatic non small cell lung cancer"/><FilterOption id="212" count="26" label="Motor neurone disease"/><FilterOption id="427" count="26" label="Uterine cervix tumor"/><FilterOption id="3771" count="25" label="Idiopathic pulmonary fibrosis"/><FilterOption id="224" count="25" label="Myocardial infarction"/><FilterOption id="20" count="25" label="Pain"/><FilterOption id="1735" count="24" label="Chronic myelocytic leukemia"/><FilterOption id="1749" count="24" label="Diffuse large B-cell lymphoma"/><FilterOption id="170" count="24" label="Huntingtons chorea"/><FilterOption id="1240" count="24" label="Mesothelioma"/><FilterOption id="161" count="23" label="Hodgkins disease"/><FilterOption id="999" count="23" label="Renal tumor"/><FilterOption id="42" count="22" label="Bladder tumor"/><FilterOption id="55" count="22" label="Cardiac failure"/><FilterOption id="1011" count="22" label="Esophagus tumor"/><FilterOption id="153" count="22" label="Hepatitis C virus infection"/><FilterOption id="1744" count="22" label="Mantle cell lymphoma"/><FilterOption id="1069" count="22" label="Metastasis"/><FilterOption id="3658" count="22" label="Metastatic colorectal cancer"/><FilterOption id="57" count="21" label="Cardiovascular disease"/><FilterOption id="3657" count="20" label="Metastatic breast cancer"/><FilterOption id="3669" count="20" label="Metastatic pancreas cancer"/><FilterOption id="1128" count="20" label="Neuroendocrine tumor"/><FilterOption id="3083" count="20" label="Peritoneal tumor"/><FilterOption id="1105" count="20" label="Scleroderma"/><FilterOption id="347" count="20" label="Wound healing"/><FilterOption id="1295" count="19" label="Neuropathic pain"/><FilterOption id="1867" count="19" label="Pulmonary hypertension"/><FilterOption id="299" count="19" label="Schizophrenia"/><FilterOption id="303" count="19" label="Sickle cell anemia"/><FilterOption id="1754" count="18" label="Cutaneous T-cell lymphoma"/><FilterOption id="93" count="18" label="Depression"/><FilterOption id="131" count="18" label="Gastrointestinal tumor"/><FilterOption id="3666" count="18" label="Metastatic stomach cancer"/><FilterOption id="2380" count="17" label="Bladder cancer"/><FilterOption id="233" count="17" label="Neurodegenerative disease"/><FilterOption id="3378" count="17" label="Soft tissue sarcoma"/><FilterOption id="1728" count="16" label="Acute lymphoblastic leukemia"/><FilterOption id="54" count="16" label="Carcinoma"/><FilterOption id="655" count="16" label="Metabolic disorder"/><FilterOption id="245" count="16" label="Osteoarthritis"/><FilterOption id="60" count="15" label="Central nervous system disease"/><FilterOption id="119" count="15" label="Epilepsy"/><FilterOption id="2243" count="15" label="Fallopian tube cancer"/><FilterOption id="1127" count="15" label="Fibrosis"/></Filter><Filter label="Regulatory Designations" name="drugRegulatoryDesignations" total="19"><FilterOption id="1" count="3231" label="Orphan Drug"/><FilterOption id="2" count="586" label="Fast Track"/><FilterOption id="3" count="187" label="Breakthrough Therapy"/><FilterOption id="9" count="156" label="Paediatric Investigation Plan"/><FilterOption id="11" count="141" label="Priority Review"/><FilterOption id="5" count="123" label="Accelerated Approval"/><FilterOption id="13" count="110" label="Rare Pediatric Disease"/><FilterOption id="10" count="46" label="PRIME"/><FilterOption id="16" count="32" label="Promising Innovative Medicine"/><FilterOption id="12" count="26" label="Qualified Infectious Disease Product"/><FilterOption id="4" count="23" label="Advanced Therapy Medicinal Product"/><FilterOption id="17" count="21" label="Regenerative Medicine Advanced Therapy"/><FilterOption id="14" count="13" label="Sakigake"/><FilterOption id="6" count="9" label="Animal Rule"/><FilterOption id="7" count="7" label="Emergency Use Authorization"/><FilterOption id="19" count="6" label="Special Review Project"/><FilterOption id="8" count="3" label="New Active Substance"/><FilterOption id="18" count="2" label="National Science and Technology Major Project"/><FilterOption id="15" count="2" label="Tropical Disease Priority Review"/></Filter><Filter label="Primary Actions" name="actionsPrimary" total="100"><FilterOption id="138" count="29" label="DNA polymerase inhibitor"/><FilterOption id="3848" count="27" label="VEGF-2 receptor antagonist"/><FilterOption id="3806" count="26" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="142" count="25" label="Topoisomerase II inhibitor"/><FilterOption id="3808" count="24" label="Kit tyrosine kinase inhibitor"/><FilterOption id="3191" count="21" label="Glucocorticoid receptor agonist"/><FilterOption id="2574" count="21" label="Histone deacetylase inhibitor"/><FilterOption id="498" count="21" label="Sodium channel inhibitor"/><FilterOption id="10240" count="20" label="mTOR inhibitor"/><FilterOption id="740" count="18" label="Epidermal growth factor receptor antagonist"/><FilterOption id="474" count="17" label="Hemoglobin modulator"/><FilterOption id="1722" count="17" label="VEGF receptor antagonist"/><FilterOption id="3846" count="17" label="VEGF-1 receptor antagonist"/><FilterOption id="3850" count="16" label="VEGF-3 receptor antagonist"/><FilterOption id="621" count="15" label="Amyloid protein deposition inhibitor"/><FilterOption id="3756" count="15" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="115" count="15" label="Factor VIII agonist"/><FilterOption id="5023" count="14" label="CD3 modulator"/><FilterOption id="141" count="14" label="Topoisomerase I inhibitor"/><FilterOption id="4010" count="13" label="Calcineurin inhibitor"/><FilterOption id="21072" count="13" label="Growth hormone ligand"/><FilterOption id="281" count="13" label="NMDA receptor antagonist"/><FilterOption id="948" count="13" label="PDGF receptor antagonist"/><FilterOption id="1120" count="13" label="Somatostatin receptor agonist"/><FilterOption id="81" count="12" label="Benzodiazepine receptor agonist"/><FilterOption id="327" count="12" label="PGI2 agonist"/><FilterOption id="1575" count="12" label="Phosphoinositide 3-kinase inhibitor"/><FilterOption id="3524" count="11" label="Abl tyrosine kinase inhibitor"/><FilterOption id="13571" count="11" label="Bcr protein inhibitor"/><FilterOption id="3154" count="11" label="CSF-1 antagonist"/><FilterOption id="20949" count="11" label="DMD gene modulator"/><FilterOption id="48489" count="11" label="PDGF receptor alpha antagonist"/><FilterOption id="11183" count="11" label="Phosphoinositide-3 kinase delta inhibitor"/><FilterOption id="135" count="10" label="DHFR inhibitor"/><FilterOption id="1716" count="10" label="Dihydroorotate dehydrogenase inhibitor"/><FilterOption id="168" count="10" label="FGF receptor antagonist"/><FilterOption id="3688" count="10" label="FGF3 receptor antagonist"/><FilterOption id="1832" count="10" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="385" count="10" label="Protein tyrosine kinase inhibitor"/><FilterOption id="541" count="10" label="Tubulin receptor antagonist"/><FilterOption id="3859" count="9" label="AKT protein kinase inhibitor"/><FilterOption id="5085" count="9" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="431" count="9" label="DNA gyrase inhibitor"/><FilterOption id="112" count="9" label="Factor IX agonist"/><FilterOption id="419" count="9" label="Factor VIIa agonist"/><FilterOption id="3682" count="9" label="FGF1 receptor antagonist"/><FilterOption id="7847" count="9" label="Histone deacetylase-3 inhibitor"/><FilterOption id="471" count="9" label="IL-6 receptor antagonist"/><FilterOption id="3564" count="9" label="Jak2 tyrosine kinase inhibitor"/><FilterOption id="48492" count="9" label="PDGF receptor beta antagonist"/><FilterOption id="2581" count="8" label="Cannabinoid CB2 receptor agonist"/><FilterOption id="1104" count="8" label="Chloride channel modulator"/><FilterOption id="3137" count="8" label="CXCR4 chemokine antagonist"/><FilterOption id="6512" count="8" label="DNA methyltransferase inhibitor"/><FilterOption id="770" count="8" label="Endothelin ET-A receptor antagonist"/><FilterOption id="3685" count="8" label="FGF2 receptor antagonist"/><FilterOption id="7928" count="8" label="GDF-8 antagonist"/><FilterOption id="7841" count="8" label="Histone deacetylase-1 inhibitor"/><FilterOption id="7844" count="8" label="Histone deacetylase-2 inhibitor"/><FilterOption id="1016" count="8" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="3252" count="8" label="Insulin-like growth factor 1 receptor antagonist"/><FilterOption id="2653" count="8" label="Nuclear factor kappa B inhibitor"/><FilterOption id="3576" count="8" label="Src tyrosine kinase inhibitor"/><FilterOption id="59" count="7" label="Androgen receptor agonist"/><FilterOption id="8255" count="7" label="APRIL receptor modulator"/><FilterOption id="5080" count="7" label="B-lymphocyte antigen CD19 modulator"/><FilterOption id="38" count="7" label="Beta adrenoceptor antagonist"/><FilterOption id="1001" count="7" label="Cyclooxygenase 2 inhibitor"/><FilterOption id="675" count="7" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="12481" count="7" label="Interleukin-2 ligand"/><FilterOption id="777" count="7" label="Lanosterol-14 demethylase inhibitor"/><FilterOption id="2511" count="7" label="MAP kinase inhibitor"/><FilterOption id="4548" count="7" label="Raf B protein kinase inhibitor"/><FilterOption id="347" count="7" label="RNA polymerase inhibitor"/><FilterOption id="499" count="7" label="Tubulin binding agent"/><FilterOption id="732" count="6" label="Alpha 1 antitrypsin stimulator"/><FilterOption id="3742" count="6" label="Axl tyrosine kinase receptor inhibitor"/><FilterOption id="3592" count="6" label="Btk tyrosine kinase inhibitor"/><FilterOption id="5121" count="6" label="CD33 antagonist"/><FilterOption id="10233" count="6" label="CFTR stimulator"/><FilterOption id="410" count="6" label="GM-CSF receptor agonist"/><FilterOption id="7856" count="6" label="Histone deacetylase-6 inhibitor"/><FilterOption id="1919" count="6" label="Insulin sensitizer"/><FilterOption id="4762" count="6" label="MEK-1 protein kinase inhibitor"/><FilterOption id="76090" count="6" label="mTOR complex 1 inhibitor"/><FilterOption id="4917" count="6" label="Proteasome inhibitor"/><FilterOption id="10451" count="6" label="Ras GTPase inhibitor"/><FilterOption id="3818" count="6" label="Ret tyrosine kinase receptor inhibitor"/><FilterOption id="51" count="5" label="Alpha 1 proteinase inhibitor"/><FilterOption id="3736" count="5" label="Anaplastic lymphoma kinase receptor inhibitor"/><FilterOption id="4418" count="5" label="Aurora protein kinase 1 inhibitor"/><FilterOption id="4420" count="5" label="Aurora protein kinase 2 inhibitor"/><FilterOption id="3755" count="5" label="Erbb2 tyrosine kinase receptor modulator"/><FilterOption id="8012" count="5" label="Hsp 90 inhibitor"/><FilterOption id="4764" count="5" label="MEK-2 protein kinase inhibitor"/><FilterOption id="1833" count="5" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="2609" count="5" label="P selectin antagonist"/><FilterOption id="778" count="5" label="PDE 5 inhibitor"/><FilterOption id="346" count="5" label="Ribonucleotide reductase inhibitor"/><FilterOption id="3826" count="5" label="Ros1 tyrosine kinase receptor inhibitor"/></Filter><Filter label="Primary Companies" name="companiesPrimary" total="100"><FilterOption id="23137" count="51" label="Novartis AG"/><FilterOption id="18767" count="51" label="Pfizer Inc"/><FilterOption id="19446" count="37" label="Roche Holding AG"/><FilterOption id="24652" count="35" label="Shire plc"/><FilterOption id="1009547" count="30" label="Sanofi SA"/><FilterOption id="20300" count="30" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="15414" count="28" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="15331" count="26" label="Celgene Corp"/><FilterOption id="15872" count="26" label="Eisai Co Ltd"/><FilterOption id="14109" count="24" label="Amgen Inc"/><FilterOption id="16450" count="24" label="Gilead Sciences Inc"/><FilterOption id="28355" count="24" label="GlaxoSmithKline plc"/><FilterOption id="18077" count="24" label="Merck &amp; Co Inc"/><FilterOption id="14455" count="20" label="Bayer AG"/><FilterOption id="1013295" count="19" label="Astellas Pharma Inc"/><FilterOption id="16299" count="19" label="Sanofi Genzyme"/><FilterOption id="1072507" count="18" label="AbbVie Inc"/><FilterOption id="1005244" count="18" label="Biogen Inc"/><FilterOption id="19453" count="18" label="Genentech Inc"/><FilterOption id="17332" count="18" label="Johnson &amp; Johnson"/><FilterOption id="28921" count="18" label="Swedish Orphan Biovitrum AB"/><FilterOption id="15065" count="16" label="Bristol-Myers Squibb Co"/><FilterOption id="1042596" count="16" label="Kyowa Hakko Kirin Co Ltd"/><FilterOption id="18681" count="16" label="Ono Pharmaceutical Co Ltd"/><FilterOption id="20348" count="16" label="Teva Pharmaceutical Industries Ltd"/><FilterOption id="14881" count="14" label="Boehringer Ingelheim International GmbH"/><FilterOption id="20452" count="14" label="UCB SA"/><FilterOption id="1088700" count="13" label="Allergan plc"/><FilterOption id="1063950" count="13" label="Biotoscana International"/><FilterOption id="15381" count="13" label="Chiesi Farmaceutici SpA"/><FilterOption id="17810" count="13" label="Eli Lilly &amp; Co"/><FilterOption id="17259" count="13" label="Ipsen"/><FilterOption id="1023179" count="13" label="Lee's Pharmaceutical Holdings Limited"/><FilterOption id="29943" count="13" label="Medison Pharma Ltd"/><FilterOption id="14190" count="12" label="AstraZeneca plc"/><FilterOption id="17392" count="11" label="Janssen-Cilag Ltd"/><FilterOption id="18439" count="11" label="Mylan NV"/><FilterOption id="18614" count="11" label="Novo Nordisk A/S"/><FilterOption id="1017117" count="11" label="Sumitomo Dainippon Pharma Co Ltd"/><FilterOption id="1007640" count="10" label="CSL Behring LLC"/><FilterOption id="19862" count="10" label="Merck Serono SA"/><FilterOption id="18552" count="10" label="Nippon Shinyaku Co Ltd"/><FilterOption id="14240" count="10" label="Sarepta Therapeutics Inc"/><FilterOption id="25861" count="9" label="BioMarin Pharmaceutical Inc"/><FilterOption id="1017506" count="9" label="Daiichi Sankyo Co Ltd"/><FilterOption id="1053335" count="9" label="Horizon Pharma plc"/><FilterOption id="1035060" count="9" label="Mitsubishi Tanabe Pharma Corp"/><FilterOption id="1123260" count="9" label="Orchard Therapeutics Ltd"/><FilterOption id="18717" count="9" label="Otsuka Pharmaceutical Co Ltd"/><FilterOption id="27477" count="9" label="Paladin Labs Inc"/><FilterOption id="21991" count="9" label="Takeda Oncology"/><FilterOption id="17058" count="8" label="Bausch Health Companies Inc"/><FilterOption id="16283" count="8" label="Genethon"/><FilterOption id="26997" count="8" label="Janssen Biotech Inc"/><FilterOption id="19946" count="8" label="Leadiant Biosciences Inc"/><FilterOption id="1085756" count="8" label="Mallinckrodt plc"/><FilterOption id="20518" count="8" label="National Institutes of Health"/><FilterOption id="24154" count="8" label="Recordati SpA"/><FilterOption id="25439" count="8" label="United Therapeutics Corp"/><FilterOption id="13979" count="7" label="Alexion Pharmaceuticals Inc"/><FilterOption id="1153354" count="7" label="Alfasigma SpA"/><FilterOption id="29387" count="7" label="Dr Reddy's Laboratories Ltd"/><FilterOption id="1108651" count="7" label="MeiraGTx"/><FilterOption id="24064" count="7" label="Orphan Europe SARL"/><FilterOption id="19214" count="7" label="Regeneron Pharmaceuticals Inc"/><FilterOption id="1044298" count="7" label="Specialised Therapeutics Australia Pty Ltd"/><FilterOption id="18720" count="7" label="Taiho Pharmaceutical Co Ltd"/><FilterOption id="1179286" count="6" label="Acrotech Biopharma LLC"/><FilterOption id="1008173" count="6" label="AOP Orphan Pharmaceuticals AG"/><FilterOption id="1063251" count="6" label="BeiGene Co Ltd"/><FilterOption id="1013599" count="6" label="Drugs for Neglected Diseases Initiative"/><FilterOption id="16581" count="6" label="Grifols SA"/><FilterOption id="19986" count="6" label="Handok Inc"/><FilterOption id="18008" count="6" label="MedImmune LLC"/><FilterOption id="26786" count="6" label="MegaPharm Ltd"/><FilterOption id="18090" count="6" label="Merck Sharp &amp; Dohme Ltd"/><FilterOption id="1072251" count="6" label="Therapeutics for Rare and Neglected Diseases"/><FilterOption id="1062138" count="6" label="Ultragenyx Pharmaceutical Inc"/><FilterOption id="20739" count="6" label="Vertex Pharmaceuticals Inc"/><FilterOption id="1016672" count="5" label="3SBio Inc"/><FilterOption id="22881" count="5" label="Abeona Therapeutics Inc"/><FilterOption id="30577" count="5" label="AGTC"/><FilterOption id="14061" count="5" label="Almirall Prodesfarma SA"/><FilterOption id="14303" count="5" label="Asahi Kasei Pharma Corp"/><FilterOption id="1086349" count="5" label="Audentes Therapeutics Inc"/><FilterOption id="25218" count="5" label="Aventis Pharma AG"/><FilterOption id="1143045" count="5" label="Bioverativ Inc"/><FilterOption id="1037227" count="5" label="BL&amp;H Co Ltd"/><FilterOption id="15266" count="5" label="BTG plc"/><FilterOption id="15620" count="5" label="Debiopharm SA"/><FilterOption id="16583" count="5" label="GC Pharma"/><FilterOption id="16611" count="5" label="Hanmi Pharmaceutical Co Ltd"/><FilterOption id="17216" count="5" label="Incyte Corp"/><FilterOption id="18535" count="5" label="Nippon Kayaku Co Ltd"/><FilterOption id="1110054" count="5" label="Pint Pharma"/><FilterOption id="28066" count="5" label="PTC Therapeutics Inc"/><FilterOption id="1069812" count="5" label="Retrophin Inc"/><FilterOption id="1113858" count="5" label="Seqirus"/><FilterOption id="19863" count="5" label="Servier"/><FilterOption id="19898" count="5" label="Shionogi &amp; Co Ltd"/></Filter><Filter label="Highest Phase" name="phaseHighest" total="12"><FilterOption id="L" count="730" label="Launched"/><FilterOption id="C2" count="687" label="Phase 2 Clinical"/><FilterOption id="DR" count="474" label="Discovery"/><FilterOption id="DX" count="395" label="Discontinued"/><FilterOption id="C3" count="348" label="Phase 3 Clinical"/><FilterOption id="NDR" count="242" label="No Development Reported"/><FilterOption id="C1" count="218" label="Phase 1 Clinical"/><FilterOption id="PR" count="44" label="Pre-registration"/><FilterOption id="R" count="39" label="Registered"/><FilterOption id="CU" count="30" label="Clinical"/><FilterOption id="W" count="16" label="Withdrawn"/><FilterOption id="S" count="8" label="Suspended"/></Filter></Filters></drugResultsOutput>